MNG1025
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.473
- MITOTIC_SPINDLE+0.446
- UV_RESPONSE_DN+0.341
- WNT_BETA_CATENIN_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.256
- ANGIOGENESIS+0.255
- TGF_BETA_SIGNALING+0.250
- IL2_STAT5_SIGNALING+0.235
- HYPOXIA+0.229
- ANDROGEN_RESPONSE+0.218
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.377
- MYC_TARGETS_V2-0.303
- KRAS_SIGNALING_DN-0.282
- PANCREAS_BETA_CELLS-0.241
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.228
- SPERMATOGENESIS-0.204
- FATTY_ACID_METABOLISM-0.173
- COAGULATION-0.151
- ESTROGEN_RESPONSE_LATE-0.150
- UV_RESPONSE_UP-0.132
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1221 | — | — | 0.823 |
| 2 | MNG454 | — | — | 0.808 |
| 3 | SJEPD030943_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.795 |
| 4 | MNG609 | — | — | 0.779 |
| 5 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.764 |
| 6 | MNG1013 | — | — | 0.760 |
| 7 | EE52CA48-EBE4-4BCA-B9BA-9AB39F8E7986 | — | — | 0.746 |
| 8 | TCGA-44-6775-01A-11R-A278-07 | — | cohortMD2 | 0.719 |
| 9 | MNG502 | — | — | 0.708 |
| 10 | TCGA-55-6642-01A-11R-1858-07 | — | cohortA3 | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.473 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.446 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.341 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.256 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.255 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.235 | Idelalisib | — uncovered |
| HYPOXIA | 0.229 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.218 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.205 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.161 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.129 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.119 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.108 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.101 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.087 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.066 | Inavolisib | — uncovered |
| COMPLEMENT | 0.045 | Inavolisib | — uncovered |